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Abstract 
Objective: Preference-based instrumental variables (PP IV) designs can identify causal effects when patients receive treatment due 
to variation in providers’ treatment preference. We offer a systematic review and methodological assessment of PP IV applications in 
health research. 
Study Design and Setting: We included studies that applied PP IV for evaluation of any treatment in any population in health 
research (PROSPERO: CRD42020165014). We searched within four databases (Medline, Web of Science, ScienceDirect, SpringerLink) 
and four journals (including full-text and title and abstract sources) between January 1, 1998, and March 5, 2020. We extracted data on 
areas of applications and methodology, including assumptions using Swanson and Hernan’s (2013) guideline. 
Results: We included 185 of 1087 identified studies. The use of PP IV has increased, being predominantly used for treatment effects 
in cancer, cardiovascular disease, and mental health. The most common PP IV was treatment variation at the facility-level, followed by 
physician- and regional-level. Only 12 percent of applications report the four main assumptions for PP IV. Selection on treatment may 
be a potential issue in 46 percent of studies. 
Conclusion: The assumptions of PP IV are not sufficiently reported in existing work. PP IV- 
studies should use reporting guidelines. © 2021 The Author(s). Published by Elsevier Inc. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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Please cite this article as: T Widding Havneraas et al Preference based instrumnomics [3–7] it is becoming a popular method for evalu-
ating causal effects in health research [8–12] . An IV is a
variable that induces random variation in treatment, which
can be used to identify treatment effects. Randomization
in a double-blind randomized controlled trial (RCT) is of-
ten presented as the ideal IV [2] , with considerable subject
matter knowledge usually required to find/defend any IVs
[13] . 
Provider preference IV (PP IV) designs use variation
in clinical practice patterns as an IV. The PP IV premise
is that variation in practice patterns reflect underlying
provider treatment preferences that induce, from the pa-ccess article under the CC BY license 
ental variables in health research rely on important and underreported
2 T. Widding-Havneraas et al. / Journal of Clinical Epidemiology xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: JCE [mNS; July 20, 2021;12:49 ] 
What is new? 
Key findings 
PP IV methods are increasingly used in health re- 
search, and across specialties. PP IV methods can es- 
timate treatment effects where RCTs are not feasible 
due to ethical or practical problems with randomiza- 
tion. Few applications of PP IV report all four main 
identifying assumptions. 
What this adds to what is known? 
This review provides an overview of applications of 
PP IV with novel data on clinical and academic area, 
reporting of assumptions, and potential selection on 
treatment bias. 
What should change now? 
Researchers should be more transparent in reporting 
assumptions when using PP as an IV and pay more 












































































tient’s perspective, random variation in patients’ treatment
status, emulating a randomized trial for a subset of pa-
tients [14] . Korn and Baumrind [15] first proposed the use
of variation in individual physicians’ preference for spe-
cific treatments as an IV. IV relies on four assumptions,
which for consistency we number according to Swanson
and Hernán’s [16] IV reporting guideline: IV must (A1)
predict treatment status (“relevance”), (A2) affect outcome
only through exposure (“exclusion”), and (A3) not share
any unmeasured causes with the outcome (“unconfound-
edness”). A fourth assumption is that treatment effects are
either constant (A4c), homogeneous (A4h) or monotonic,
i.e., the IV only affects treatment status in one direction
(A4m). 
The broader term “preference-based IV” was introduced
by Brookhart and Schneeweiss [14] who specify PP IV
studies assume (1) between-provider variation in use of
treatments, (2) patient selection or assignment to providers
is unrelated to providers’ treatment preference, and (3)
providers’ use of one treatment is independent of use of al-
ternative treatments that affect outcomes. Consequently, the
promise of circumventing unobserved confounding with PP
IV is dependent on important assumptions [14] . 
Provider preference is difficult to measure directly. Re-
searchers often measure latent provider preference as the
proportion of patients that receive treatment of interest or,
in pharmacological studies, prescriptions issued before cur-
rent prescription at physician, facility, or geographical re-
gion levels. Table 1 presents examples of common PP IV
designs. 
Please cite this article as: T. Widding-Havneraas et al., Preference-based instru
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// do1.1. Estimands and interpretation 
Suppose we are interested in the effect of a specific
medication ( D = 1 ), with treatment as usual as the alter-
native ( D = 0 ), on mortality ( Y ). In observational data,
treatment receipt is likely correlated with unobserved risk
factors of the outcome, such as patient presentation, caus-
ing confounding bias. Random variation in provider pref-
erence ( P P ) for D = 1 over D = 0 , e.g., measured as
the physician’s last prescription before current prescription
[17] , can be considered as an IV. The intuition behind IV
is that random variation in P P represents a natural source
of randomization in D. By isolating variation in D en-
tirely due to P P , IV can be used to identify causal effects
[1] , [20] . Under A1-A3 and constant (A4c) or homogenous
(A4h) effects the IV-estimator is consistent for the aver-
age treatment effect (ATE) [21] . When treatment effects
vary over patients, e.g. stronger side effects experienced
by older patients, and both IV and treatment are binary,
then, under A1-A3 and A4m, IV estimates the local av-
erage treatment effect (LATE) for a latent subpopulation
of “compliers,” who always take the treatment that corre-
sponds to the provider’s preference [6] . A caveat with PP
IV designs is that complier interpretation is complicated
because patients may comply to varying extents [14] . There
is substantial debate on the clinical and policy relevance
of the LATE estimand [22] , [23] relating to the validity and
interpretation of PP IV under various constraints, to which
we turn next. 
1.2. Validity 
Several scenarios can give rise to a valid PP IV.
Figure 1 displays data-generating models, directed acyclic
graphs (DAG) [24] , [25] , to illustrate common scenarios
and challenges. Figure 1 a, b and c provide valid PP IVs,
while Figure 1 d, e and f present PP IV violations. In all
models, treatment, D, and outcome, Y , are confounded
by unobserved variables, U , preventing identification of
the causal effect of D on Y by covariate adjustment (e.g.,
regression, matching, or weighting), motivating the search
for a suitable IV. 
Figure 1 a illustrates a model where P P does not share
unobserved risk factors with Y (unconfoundedness), di-
rectly affects D (relevance), and does not affect Y via
any mechanism other than via D (exclusion). This is of-
ten considered the best-case scenario for IV estimation. In
Figure 1 b P P is a so-called proxy IV, such as the
provider’s manifest (measurable) prescribing behavior,
which is affected by the unobserved true provider-
preference, U P P , but does not itself cause D. Most PP
IV designs follow the proxy design; it is difficult to elicit
providers’ true preferences [8] . Interpretation of proxy IV
designs is difficult. U P P is a continous variable, while P P 
is typically measured as a binary proxy. If treatment effectsmental variables in health research rely on important and underreported 
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Table 1. Common examples of provider preference instrumental variables designs: Physician, facility and regional. Examples correspond to physician 
[17] , facility [18] , and regional [19] level PP IVs. The physician example is a binary PP IV representing the instantaneous provider preference, 
alternatively prescribing patterns can be averaged over time 
Authors Study topic Instrumental variable 
Wang et al. [17] Effect of conventional vs. atypical antipsychotic 
medications (APM) on short-term mortality risk 
among elderly users. 
Physician’s preference for prescribing an atypical 
APM instead of conventional APM measured as the 
most recent APM prescription before the current 
prescription. 
Dalsgaard et al. [18] Effect of early ADHD medication on contacts with 
hospitals, emergency ward, and police, among 
children diagnosed with ADHD. 
Facility variation in propensity to prescribe 
medication measured as the share of other 
treated children in the same cohort diagnosed at 
the same facility. 
Emdin et al. [19] Effect of referral to cardiology follow-up on 
post-discharge mortality among patients with 
systolic heart failure. 
Regional variation in referral to cardiology follow-up 
defined as the proportion of patients referred to 
follow-up within a region. 
Figure 1. Models involving provider-preferences. PP is the measured provider-preference. U PP is a latent (underlying) provider-preference. D is 
treatment. Y is the outcome. U are unobserved confounders. (a) P P with a valid causal IV. (b) P P is a valid proxy IV. (c) P P is a valid IV when 
X is controlled. (d) P P is not valid as the IV directly affects Y . (e) P P is not a valid IV if the sample is selected on S as a function of D. (f) P P 





























are heterogeneous, this design will typically recover some
weighted average of heterogenous treatment effects [2] . 
In Figure 1 c P P is not random, as D and Y are con-
founded by X , e.g., shared patient and/or provider charac-
teristics. Hence, all such confounders must be controlled
for to meet A3. There is evidence of insufficient adjustment
in PP IV applications [9] . When covariates are included,
standard IV estimators obtain a variance-weighted average
of covariate-specific LATEs [26] that may, however, be
transformed into an unweighted LATE [27] . 
Figure 1 d includes direct effects of P P on Y , which
violates A3 and may occur if providers’ preference for one
treatment over another also leads them to treat patients dif-
ferently in other ways [28] . In Figure 1 e, sample selection,
S, is a function of treatment, which violates A3. This oc-Please cite this article as: T. Widding-Havneraas et al., Preference-based instrum
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// docurs, for example, when a study restricts analyses to a sub-
set of treatment options when more options are available
[21] , [29] . In this scenario, sample selection conditions on
the descendant of a collider on the path P P → D ← U →
Y , thereby opening a non-causal pathway between P P and
Y [30–33] . Selection on the treatment can also occur in
other models [21] , [30] , [32] , [34] , [35] . In Figure 1 f, P P is
not a valid IV as sample selection, S, is a descendant of
Y [32] . For example, this bias may occur a study on the
effects of ADHD medication on employment includes em-
ployed and unemployed but excludes non-employed peo-
ple. In addition to scenarios in Figure 1 , studies show (1)
monotonicity (A4m) is unlikely to hold in certain PP IV
applications [36] ; (2) PP IVs can be biased when treat-
ments are over/underused, as IV can over/underweight pa-ental variables in health research rely on important and underreported 
i.org/ 10.1016/ j.jclinepi.2021.06.006 
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tients who may not need treatment in the former/latter case
[14] ; (3) IVs must be sufficiently strong to not induce weak
IV bias ( F > 10 in first stage regressions) [37] , with recent
work suggesting a considerably higher threshold [38] . 
PP IV is among the most commonly applied IVs in
health research [8–10] , [39] , calling for scrutiny of current
practice in view of recent studies pointing out potential is-
sues with PP IV designs, including monotonicity [36] and
bias from selecting on treatment [21] . Existing reviews ei-
ther examine IVs in general [8–10,16,39] or are narrative
PP IV reviews [40] . Here we contribute to the literature
on PP IV through a systematic review focused on PP IV
applications using a search strategy involving full-text min-
ing [41] , using databases that enable complete article text
searches. We present novel data on applications, including
academic and clinical areas, reporting of IV assumptions,
potential bias from selection on treatment and strength of
various PP IV definitions. The review’s aim is to (i) pro-
vide an introduction to PP IV, (ii) systematically review
applications of PP IV in health research, and (iii) evaluate
current practice with PP IVs. 
2. Methods 
This systematic review adhered to the Preferred Re-
porting Item for Systematic Reviews and Meta-Analysis
(PRISMA) guideline (Supplementary 1) [42] and is regis-
tered in PROSPERO (CRD42020165014). 
2.1. Search strategy 
We conducted a systematic search in ScienceDirect
(full-text), SpringerLink (full-text), Medline (OVID) (ti-
tle and abstract), and Web of Science (title and abstract).
We had no language restrictions, but search words were
restricted to English. As there are no pre-defined sub-
ject heading/keywords for PP IV, we also searched spe-
cific journals identified through database searches and prior
knowledge of the literature: American Journal of Epidemi-
ology, International Journal of Epidemiology (Oxford Uni-
versity Press Journals, full-text), Health Economics (Wi-
ley Online Library, full-text), and Epidemiology (Wolters
Kluwer, title and abstract). To identify additional relevant
studies, we hand-searched reference lists of included stud-
ies. Key search words included “instrument ∗ variable ∗”,
“provider”, “physician”, “prescribing”, and “preference”. 
We combined all search results in EndNote X9 [43] and
removed duplicates. All studies were imported into Covi-
dence systematic review software [44] and remaining du-
plicates removed. Initial and full-text screening was con-
ducted independently by two reviewers (TW and either
AC or IL). Discrepancies regarding study inclusion were
resolved through consensus. Search strategies and included
study references are provided in Supplementary 2. Please cite this article as: T. Widding-Havneraas et al., Preference-based instru
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// do2.2. Eligibility 
We included all empirical health research studies using
quasi-experimental PP IV designs and real-world data. We
defined PP IV as all applications where variation in treat-
ment at either physician, facility or regional level are used
as an IV to predict treatment status [9] . Eligible studies
were peer-reviewed and used PP as an IV for any treatment
in any population from the method’s introduction (January
1, 1998) to last search date (March 5, 2020). We excluded
all studies not applying PP as an IV in health research and
studies only using simulated data. 
2.3. Data extraction 
A data extraction manual was developed for this re-
view (Supplementary 3). Consistent data extraction was
ensured by independently piloting 10 articles. We extracted
data on publication year, country (data), sample definition,
sample restricted to diagnosed population, academic disci-
pline (first author’s affiliation), clinical discipline (ICD-10
chapter), PP IV definition, PP IV category (physician, fa-
cility, or regional), treatment, outcome, F -statistics from
first stage regressions, p -values for treatment effects, and
authors specification of research question/objective and re-
sults (both in abstract). We also extracted data on whether
studies used treatment as a sample-selection criteria, the
application was part of a methodology paper, and whether
multiple methods were used (triangulation). To ensure con-
sistent data extraction, 20 percent of data was extracted in
duplicate by two independent reviewers (TW and either
AC or IL), with the remainder extracted by TW and cross-
checked by another reviewer. We e-mailed authors when
unable to find relevant information. Data available in Sup-
plementary 4. 
2.4. Quality assessment 
We use reported assumptions necessary for valid IV
designs as quality assessment and appraisal in line with
existing reviews [39] . We extracted detailed data on A1-
A3 and A4h/A4m [16] (Supplementary 3). Each condition
was given a score of 1 if reported and 0 otherwise, so the
maximum total score a study could obtain was 4. A1-A3
and A4h/A4m were extracted by two independent review-
ers for 20 percent of studies (TW and either AC or IL),
with the remainder extracted by TW. For A1-A3, a score
of 1 was given if these assumptions were acknowledged
or discussed, or, for A1 if the association between treat-
ment and IV was reported and for A3 if covariates were
included in IV-analyses (A3). For A4h/A4m, studies were
coded 1 when reporting monotonicity or homogeneity. 
2.5. Synthesis of results 
We analyzed trends in PP IV use by publication
year/topic, cross-tabulated data, and then used regressionmental variables in health research rely on important and underreported 
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for eligibility
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37 not PP IV
16 not application of PP IV
9 not an original article
3 duplicates
2 insufficient information
Studies included in 
qualitative synthesis
(n = 185)



























models to test for change in mean reported assumptions
score and proportion of significant findings over time.
One way ANOVA and Kruskal Wallis tests examined sup-
port for differences in reported assumptions scores and F -
statistics across disciplines, clinical areas, and PP IV cate-
gories. Stata SE 16.1. [45] was used for data analysis and
visualization. 
3. Results 
1087 studies were identified and included in initial
screening. 252 were assessed in full-text, with 185 meeting
inclusion criteria ( Figure 2 ). Figure 3 A indicates the yearly
number of PP IV studies in health research has increased.
3.1. Areas of application 
PP IV methods were most commonly applied in
medicine, followed by public health, and economics ( Ta-Please cite this article as: T. Widding-Havneraas et al., Preference-based instrum
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// doble 3 ). Most PP IV applications addressed treatment effects
for samples with neoplasms, followed by circulatory dis-
ease, and mental/behavioral disorders. Together these com-
prised 55% of applications. 
PP IV is increasingly used across clinical areas, with
neoplasms consistently at the top ( Figure 3 B). Most studies
use data from the US ( n = 122, 39.5%), followed by UK
( n = 26, 8.4%), Canada ( n = 21, 6.8%), Japan ( n = 20,
6.5%), and Sweden ( n = 13, 4.2%) ( Figure 3 C). The in-
cluded studies apply data from 33 countries. 
3.2. Methodological assessment 
The most frequently addressed identifying assumptions
were A1 (relevance), A3 (confounding) and A2 (exclu-
sion) ( Table 2 ). Few reported A4h or A4m. Less than
half of studies reported F -statistics from first stage regres-
sions. We did not find support for a reduction in proportion
of reported significant p -values over time (Supplementaryental variables in health research rely on important and underreported 
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Figure 3. Cumulative trends in applications of preference-based instrumental variables by publication year, clinical area, country and PP IV definition. 
(A) Publication year with studies by year as right-side y -axis. (B) Clinical field by the study population’s ICD-10 chapter: (II) Neoplasms, (IX) 
Diseases of the circulatory system, (V) Mental and behavioral disorders, (XXI) Factors influencing health status and contact with health services, 
(XX) External causes of morbidity and mortality, (IV) Endocrine, nutritional and metabolic diseases, (X) Diseases of the respiratory system, and 
remaining chapter codes in Other. (C) US and non-US applications by data used. (D) Provider-preference proxy category. One study may contain 







































S2, Table S3). Moreover, bias from selecting on treatment
may be an issue in several applications. Many studies use
multiple methods to address research questions (triangula-
tion), most commonly IV with multivariable regression or
propensity score matching. 
Mean quality assessment score (QA) was somewhat
higher in public health and pharmacology than in medicine
( Table 3 ). Small differences in QA scores were found be-
tween clinical areas and PP IV categories ( Table 3 ). We
found no support for a change in assumption reporting over
time, and also no change after Swanson and Hernán’s re-
porting guideline [16] was published (Supplementary 2,
Table S3). 
4. Discussion 
4.1. Main findings 
Our findings show PP IV is predominantly used to esti-
mate treatment effects for cancer, cardiovascular diseases,
and mental health, where valid causal inferences are crucial
in planning treatments. Nearly half of the studies provided
justification for using PP IV relative to RCT, underliningPlease cite this article as: T. Widding-Havneraas et al., Preference-based instru
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// doways in which PP IV can contribute to causal evidence
[11] . We identified more PP IV applications than exist-
ing reviews, perhaps due to mining full-texts in our initial
search; however, several years have passed since publica-
tion of relevant systematic reviews [8] , [9] , [39] . 
The most common proxy definition of PP is variation
in practice-patterns at facility-level, followed by physician-
and regional-level. A mere 12 percent of studies report
the four main assumptions (A1-A3 and A4h or A4m) for
point identification of treatment effects with IV, while 73
percent report the three main assumptions (A1-A3) nec-
essary for bounds on treatment effects. This is consistent
with Swanson and Hernán’s review [16] where relatively
few reported the fourth assumption. We found considerable
variation in how assumptions were reported, ranging from
stating assumptions without further justification to care-
ful delineations on validity concerns under given circum-
stances. The latter approach is encouraged as the validity
of PP IV can vary considerably by context. For example,
the validity of PP IV have been found to vary by database
and definition of PP [46] , [47] , where the latter may also
result in varying effect estimates [48] . Homogeneity (A4h)
or monotonicity (A4m) should receive more attention inmental variables in health research rely on important and underreported 
i.org/ 10.1016/ j.jclinepi.2021.06.006 
T. Widding-Havneraas et al. / Journal of Clinical Epidemiology xxx (xxxx) xxx 7 
ARTICLE IN PRESS 
JID: JCE [mNS; July 20, 2021;12:49 ] 
Table 2. Methodological assessment of preference-based instrumental variables. Reported values in 185 studies. (1) Studies by total reported 
assumptions (range 0-4). (2) Recurring themes: RCTs not ethically feasible, impractical due to rare outcomes, generalizability, time-consuming 
data collection. (3) Multiple methods could be used in 173 studies, 12 studies focused on methodology. (4) Sample selection fully or partially 
a function of treatment. (5) 173 studies transparently reported 1524 p-values with median 3 per study. Percent weighted by reported p-values. 
(6) Median and interquartile range (IQR) weighted by F-statistics. 279 F-statistics reported by 86/194 applications. Median 3 per study. Range 
4.2-109825. F-statistics above 104.7 (n/N, %): Overall 51/194 (26). By IV category: Physician 21/63 (33), Facility 12/76 (16), Regional 
18/55 (33). Kruskal Wallis H test for differences in F-statistics across PP IV categories ( P = .07). 
Identifying assumptions (n, %) 
Stated or empirically verified relevance (A1) 180 (98) 
Stated or discussed exclusion (A2) 157 (86) 
Stated, discussed, or adjusted for covariates for unconfoundedness (A3) 178 (97) 
Stated homogeneity (A4h) 1 (.5) 
Stated monotonicity (A4m) 21 (11) 
Quality assessment score (n, %) 1 
1 11 (6) 
2 18 (10) 
3 134 (72) 
4 22 (12) 
Justification for using PP IV over RCT (n, %) 2 86 (46) 
Triangulation (n, %) 3 133 (72) 
Selection on treatment (n, %) 4 85 (46) 
p -value for treatment effect significant at 5% level (n/N, %) 5 642/1524 (42) 
Sample size (median, IQR) 31451 (6185-78531) 
First stage F-statistic (median, IQR) 6 270 (69-399) 
F -statistic for physician PP IVs 399 (342-1871) 
F -statistic for facility PP IVs 190 (29-949) 












































future studies given recent studies on how monotonicity in
PP IVs can easily be violated [23] , [36] , [49] . 
PP IVs are most valuable in studies with considerable
unobserved confounding, large sample size and a strong
IV [50] . Most studies had relatively large sample sizes ,
generally much larger than applied in RCTs. Reported F -
statistics suggest that PP IVs are relatively strong, albeit
the wide range is similar to IVs in epidemiology more
generally [8] . Potential reporting bias implies a cautious
interpretation of our results. Around 40 percent of reported
treatment effects were statistically significant at the 5%
level. 
Publication bias may be an issue for IV applications,
and we believe a relevant next step could be to examine
z -statistics like Brodeur et al. [51] . Our findings show that
there is potential selection on treatment bias in 46 percent
of PP IV applications, lending support to concerns raised
in literature [21] , [30] . Finally, many studies combine IV
with other study designs which is particularly useful as
the combination of multiple designs with various underly-
ing assumptions can create a more comprehensive under-
standing of treatment effects [2] , [52] . 
4.2. Strengths and limitations 
This review was pre-registered in PROSPERO and was
conducted accordingly, as described in the methods sec-Please cite this article as: T. Widding-Havneraas et al., Preference-based instrum
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// dotion. There are some limitations of this study. There is
no keyword or search term that identifies with high speci-
ficity and sensitivity empirical studies applying PP IV ap-
proaches. We aimed to mitigate this limitation by full-
text searches. Additional studies could probably have been
identified by full-text search in additional journals. We
applied only English-language search terms, which may
have caused selection bias. Publication bias is difficult to
assess when including studies across aims, subjects and
disciplines, and no funnel-plot was attempted. Search for
p -hacking strategies could identify publication bias [51] ,
but we did not attempt this. As there is no developed
methodological evaluation tool for critical appraisal of PP
IV studies, unlike risk of bias appraisal in RCTs, our qual-
ity assessment and appraisal relies on the reporting of IV
assumptions in line with existing IV-reviews [39] . 
4.3. Contribution 
This review contributes to existing knowledge on PP
IV in three ways. First, to our knowledge this is the first
systematic review with an explicit focus on PP as an IV,
which is warranted as this is among the most applied IVs
in health research [8] , [9] , [39] . Second, we present novel
data on PP IV applications on academic and clinical top-
ics, reporting of IV assumptions, and potential selectionental variables in health research rely on important and underreported 
i.org/ 10.1016/ j.jclinepi.2021.06.006 
8 T. Widding-Havneraas et al. / Journal of Clinical Epidemiology xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: JCE [mNS; July 20, 2021;12:49 ] 
Table 3. Areas of applications and quality assessment score by academic discipline, clinical area, and PP IV category. Quality assessment (QA) score 
range from 0-4 reported assumptions. Discipline defined by first author’s affiliation. Mean QA score differed by discipline (one-way ANOVA: P 
= .009). Pairwise comparisons show that public health differ from medicine ( P < .001), as do pharmacology ( P = .04). (2) Consists of general 
and other subdisciplines not specified. (3) Includes epidemiology and biostatistics. (4) Due to some studies including several ICD-chapter 
codes, the total is 191. Mean QA score differed by clinical areas (Kruskal Wallis H test: P = .029). Dunn’s pairwise comparisons test supported 
following differences: IV, V, IX relative to II; X, XX relative to IV; X, XX, Other relative to V; X, XX, Other relative to IX. (5) Due to some studies 
using multiple PP IV categories, the total is 194. Mean QA score varied by PP IV categories (one-way ANOVA: P = .013). Pairwise comparisons 
showed that physician IVs differed from facility IVs ( P = .003). 
Areas of 
application 
Quality assessment score (n, %) 
n (%) 1 2 3 4 Mean 
Discipline 1 
Medicine 2 60 (32) 7 (11.5) 8 (13.1) 44 (72.1) 2 (3.3) 2.7 
Surgery 13 (7) 1 (7.7) 2 (15.4) 10 (76.9) 0 (0) 2.7 
Pharmacology 13 (7) 0 (0) 1 (7.7) 10 (77.9) 2 (15.4) 3.1 
Psychiatry 2 (1) 0 (0) 0 (0) 2 (100) 0 (0) 3 
Public health 3 80 (43) 3 (3.8) 4 (5) 57 (71) 16 (20) 3.1 
Economics 17 (9) 0 (0) 3 (17.7) 12 (70.6) 2 (11.8) 2.9 
Total 185 (100) 11 (5.8) 18 (9.5) 138 (73) 22 (11.6) 2.9 
ICD-10 Chapter 4 
Neoplasms (II) 45 (23) 1 (2.2) 6 (13.3) 37 (82.2) 1 (2.2) 2.8 
Diseases of the circulatory system (IX) 36 (19) 2 (5.6) 0 (0) 27 (75) 7 (19.4) 3.1 
Mental and behavioral disorders (V) 26 (13) 0 (0) 1 (3.9) 20 (77) 5 (19.2) 3.1 
Factors influencing health status and contact with health 
services (XXI) 
18 (9) 0 (0) 4 (22) 12 (66.7) 2 (11) 2.9 
External causes of morbidity and mortality (XX) 11 (6) 2 (18.2) 1 (9.1) 8 (72.7) 0 (0) 2.5 
Endocrine, nutritional, and metabolic diseases (IV) 9 (5) 1 (11.1) 0 (0) 5 (55.6) 3 (33.3) 3.1 
Diseases of the respiratory system (X) 8 (4) 2 (25) 1 (12.5) 4 (50) 1 (12.5) 2.5 
Other 38 (20) 3 (7.9) 5 (13.2) 26 (68.4) 4 (10.5) 2.8 
Total 191 (100) 11 (5.8) 18 (9.4) 139 (72.8) 23 (12) 2.9 
PP IV category 5 
Facility 76 (39.2) 7 (9.2) 14 (18.4) 45 (59.2) 10 (13.2) 2.8 
Physician 63 (32.4) 3 (4.8) 1 (1.6) 46 (73) 13 (20.6) 3.1 
Regional 55 (28.4) 1 (1.8) 3 (5.5) 49 (89.1) 2 (3.6) 2.9 































on treatment bias, and discuss current practice. Third, we
highlight specific design considerations raised in the PP IV
methodological literature. 
4.4. Implications 
The credibility of the design requires transparent re-
porting. In line with former reviews on the use of IVs in
health research [8] , we find more explicit reporting of as-
sumptions can make it easier to examine support for causal
inference [see also, 16, 39, 54]. Future PP IV studies
should draw on reporting guidelines [8,16] , triangulation
[2] , DAGs [49] , and falsification tests [54] . 
The PP variable must meet strong assumptions to be
considered a plausible IV. When assumptions are violated,
estimates can be biased in counterintuitive ways [2] , [53] .
Hence, there is a trade-off between accounting for unob-
served confounding and introducing bias where the deci-
sion to apply PP IV should factor in strength of confound-
ing and credibility of the PP IV [28] , [53] . Moreover, IVs
often have wide confidence intervals and may be prone toPlease cite this article as: T. Widding-Havneraas et al., Preference-based instru
assumptions: A systematic review, Journal of Clinical Epidemiology, https:// dop -hacking compared to other common quasi-experimental
designs [51] . While application of any method requires
care, the combination of all aspects that go into valid
causal inference from PP IVs warrant extra attention. 
5. Conclusion 
This systematic review provides evidence that PP is
commonly used as an IV in health research, particularly
for cancer, cardiovascular diseases and mental health, and
presents novel data on methodological considerations. The
review identified more applications of PP IV than existing
reviews and expanded on reporting assumptions. We en-
courage authors and journals to emphasize reporting guide-
lines [8,16] in studies using PP IV. Empirical studies ap-
plying PP IV methods have merit to inform clinical and
policy decisions on questions challenging or unfeasible to
address with RCTs, but impact rests on the credibility of
the study design. mental variables in health research rely on important and underreported 
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Supplementary material associated with this article can
be found, in the online version, at doi: 10.1016/j.jclinepi.
2021.06.006 . 
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